Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Minor intron splicing restricts E2F transcription factor activity in RB-deregulated prostate cancer

Created on 16 Nov 2026

Authors

Thienger, P., Paassen, I., Maier, B., Wang, C., Dayan, D., Benjak, A., Fuchs, V., Lehner, M., Girardini, K., Rosenstock, C., Rodriguez, A., Brandt, L. P., Morrissey, C., Coleman, I., Augspach, A., Clarke, D., Gerstein, M., Kanadia, R. N., Rubin, M. A.

Abstract

Castration-resistant prostate cancer with neuroendocrine differentiation (CRPC-NE) arises in RB1-mutated lineage plastic cells in response to androgen receptor (AR)-targeted therapies. RB1 loss leads to constitutive E2F activation and cylin-dependent kinase (CDK) inhibitor resistance, making it challenging to restrict E2F activity. A post-transcriptional node is that typical E2Fs contain a rare but highly conserved minor intron, processed by the minor spliceosome (MiS). In an in vivo CRISPR screen, we nominate the MiS as the strongest dependency, and U6atac correlates strongest with E2F transcriptional programs in a clinical CRPC cohort. U6atac depletion led to mis-splicing of typical E2Fs, cell cycle arrest, and translation of a minor intron-containing E2F1 isoform (E2F1-MIRI) as a pharmacodynamic biomarker. Combined E2F activator depletion, induced further neuroendocrine (NE) specification. U6atac depletion shifted NE identity along the ASCL1 axis without the secretory granule program, and induced cell-surface antigens including DLL3, nominating MiS inhibition as a combination partner for antigen-directed agents.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 16 Nov 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement